Glial cell-line derived neurotrophic factor is essential for electroconvulsive shock-induced neuroprotection in an animal model of Parkinson's disease

Neuroscience

Volumn 195, Issue , 2011, Pages 100-111

  Anastasia A ^a   Wojnacki, J ^a   de Erausquin, G A ^b   Masco D H ^a  

^a UNIVERSIDAD NACIONAL DE CÓRDOBA   (Argentina)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

6 OHDA; Astrocytic reaction; Electroconvulsive; GDNF; Neuroprotection; Parkinson's disease

Indexed keywords

GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; OXIDOPAMINE; PROTEIN ANTIBODY; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; CONTROLLED STUDY; CORPUS STRIATUM; ELECTROCONVULSIVE THERAPY; IMMUNOHISTOCHEMISTRY; MALE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; STAINING; SUBSTANTIA NIGRA;

ANIMALS; CELL SURVIVAL; ELECTROCONVULSIVE THERAPY; ELECTROSHOCK; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; IMMUNOHISTOCHEMISTRY; MALE; NEURONS; PARKINSONIAN DISORDERS; RATS; RATS, WISTAR;

EID: 80053568617     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2011.08.019     Document Type: Article

References (108)

1. Abe M., Kimoto H., Eto R., Sasaki T., Kato H., Kasahara J., Araki T. Postnatal development of neurons, interneurons and glial cells in the substantia nigra of mice. Cell Mol Neurobiol 2010, 30:917-928.
2. Altar C.A., DeStefano P.S. Neurotrophin trafficking by anterograde transport. Trends Neurosci 1998, 21:433-437.
3. Altar C.A., Laeng P., Jurata L.W., Crockman J.A., Lemire A., Bullard J., Bukhman Y.V., Young T.A., Charles V., Palfreyman M.G. Electroconvulsive seizures regulates gene expression of distinct neurotrophic signaling pathways. J Neurosci 2004, 24:2667-2677.
4. Anastasía A., De Erausquin G.A., Wojnacki J., Mascó D.H. Protection of dopaminergic neurons by electroconvulsive shock in an animal model of Parkinson's disease. J Neurochem 2007, 103:1542-1552.
5. Anastasía A., Torre L., De Erausquin G.A., Mascó D.H. Enriched environment protects the nigrostriatal dopaminergic system and induces astroglial reaction in the 6-OHDA rat model of Parkinson's disease. J Neurochem 2009, 109:755-765.
6. Andersen K., Balldin J., Gottfries C.G., Granérus A.K., Modigh K., Sevennerholm L., Wallin A. A double-blind evaluation of electroconvulsive therapy in Parkinson's disease with "on-off" phenomena. Acta Neurol Scand 1987, 76:191-199.
7. Angelucci F., Aloe L., Jiménez-Vasquez P., Mathé A.A. Electroconvulsive stimuli alter the regional concentrations of nerve growth factor, brain-derived neurotrophic factor, and glial cell line-derived neurotrophic factor in adult rat brain. J ECT 2002, 18:138-143.
8. Angelucci F., Aloe L., Jiménez-Vasquez P., Mathé A.A. Electroconvulsive stimuli alter nerve growth factor but not brain-derived neurotrophic factor concentrations in brains of a rat model of depression. Neuropeptides 2003, 37:51-56.
9. Aponso P.M., Faull R.L., Connor B. Increased progenitor cell proliferation and astrogenesis in the partial progressive 6-hydroxydopamine model of Parkinson's disease. Neuroscience 2008, 151:1142-1153.
10. Arenas E., Trupp M., Akerud P., Ibáñes C.F. GDNF prevents degeneration and promotes the phenotype of brain noradrenergic neurons in vivo. Neuron 1995, 15:1465-1473.
11. Balldin J., Granérus A.K., Lindstedt G., Modigh K., Wålinder J. Predictors for improvement after electroconvulsive therapy in parkinsonian patients with on-off symptoms. J Neural Transm 1981, 52:199-211.
12. Barroso-Chinea P., Cruz-Muros I., Aymerich M.S., Rodriguez Diaz M. Striatal expression of GDNF and differential vulnerability of midbrain dopaminergic cells. Eur J Neurosci 2005, 21:1815-1827.
13. Batchelor P.E., Liberatore G.T., Wong J.Y.F., Porritt M.J., Frerichs F., Donnan G.A., Howells D.W. Activated macrophages and microglia induce dopaminergic sprouting in the injured striatum and express brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor. J Neurosci 1999, 19:1708-1716.
14. Beck K.D., Valverde J., Alexl T., Poulsen K., Motaff B., Vandlen R.A., Rosenthal A., Hefti F. Mesencephalic dopamine neurons protected by GDNF from axotomy-induced degeneration in adult brain. Nature 1995, 373:339-341.
15. Bekinschtein P., Cammarota M., Müller Igaz L.M., Bevilaqua L.R., Izquierdo I., Medina J.H. Persistence of long-term memory storage requires a late protein synthesis- and BDNF-dependent phase in the hippocampus. Neuron 2007, 53:261-277.
16. Bilang-Bleuel A., Revah F., Colin P., Locquet I., Robert J.-J., Mallet J., Horellou P. Intrastriatal injection of an adenoviral vector expressing glial-cell-line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson disease. Proc Natl Acad Sci USA 1997, 94:8818-8823.
17. Björklund A., Rosenblad C., Winkler C., Kirik D. Studies on neuroprotective and regenerative effects of GDNF in a partial lesion model of Parkinson's disease. Neurobiol Dis 1997, 4:186-200.
18. Bowenkamp K., David D., Lapehak P., Henry M., Granholm A., Hoffer B.J., Mahalik T. 6-hydroxydopamine induces the loss of the dopaminergic phenotype in substantia nigra neurons of the rat. Exp Brain Res 1996, 111:7-9.
19. Bresjanac M., Antauer G. Reactive astrocytes of the quinolinic acid-lesioned rat striatum express GFRalpha1 as well as GDNF in vivo. Exp Neurol 2000, 164:53-59.
20. Burke R.E. GDNF as a candidate striatal target-derived neurotrophic factor for the development of substantia nigra dopamine neurons. J Neural Transm Supplement 2006, 70:41-45.
21. Choi-Lundberg D.L., Bohn M.C. Ontogeny and distribution of glial cell line-derived neurotrophic factor (GDNF) mRNA in rat. Brain Res Dev Brain Res 1995, 85:80-88.
22. Choi-Lundberg D.L., Lin Q., Chang Y.N., Chiang Y.L., Hay C.M., Mohajeri H., Davidson B.L., Bohn M.C. Dopaminergic neurons protected from degeneration by GDNF gene therapy. Science 1997, 275:838-841.
23. Conti G., Gale K., Kondratyev A. Immunohistochemical evaluation of the protein expression of nerve growth factor and its TrkA receptor in rat limbic regions following electroshock seizures. Neurosci Res 2009, 65:201-209.
24. Damier P., Hirsch E.C., Agid Y., Graybiel A.M. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain 1999, 122:1437-1448.
25. Dauer W., Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003, 39:889-909.
26. Depino A.M., Earl C., Kaczmarczyk E., Ferrari C., Besedovsky H., del Rey A., Pitossi F.J., Oertel W.H. Microglial activation with atypical proinflammatory cytokine expression in a rat model of Parkinson's disease. Eur J Neurosci 2003, 18:2731-2742.
27. Ding Y.M., Jaumotte J.D., Signore A.P., Zigmond M.J. Effects of 6-hydroxydopamine on primary cultures of substantia nigra: specific damage to dopamine neurons and the impact of glial cell line-derived neurotrophic factor. J Neurochem 2004, 89:776-787.
28. Duman R.S., Vaidya V.A. Molecular and cellular actions of chronic electroconvulsive seizures. J ECT 1998, 14:181-193.
29. Fall P.A., Ekberg S., Granérus A.K., Granérus G. ECT in Parkinson's disease-dopamine transporter visualised by [123I]-beta-CIT SPECT. J Neural Transm 2000, 107:997-1008.
30. Follesa P., Gale K., Mocchetti I. Regional and temporal pattern of expression of nerve growth factor and basic fibroblast growth factor mRNA in rat brain following electroconvulsive shock. Exp Neurol 1994, 127:37-44.
31. Fregni F., Simon D., Wu A., Pascual-Leone A. Non-invasive brain stimulation for Parkinson's disease: a systematic review and meta-analysis of the literature. J Neurol Neurosurg Psychiatry 2005, 76:1614-1623.
32. Freundlieb N., François C., Tandé D., Oertel W.H., Hirsch E.C., Höglinger G.U. Dopaminergic substantia nigra neurons project topographically organized to the subventricular zone and stimulate precursor cell proliferation in aged primates. J Neurosci 2006, 26:2321-2325.
33. Fujikilow M., Abea E., Nagaia Y., Shiqia K., Kuboa T., Ishiia K., Abea T., Kobayashia H. Electroconvulsive seizure-induced VEGF is correlated with neuroprotective effects against cerebral infarction: involvement of the phosphatidylinositol-3 kinase/Akt pathway. Exp Neurol 2010, 225:377-383.
34. Gallinek A. Electric convulsive therapy in geriatrics. N Y State J Med 1947, 47:1233-1241.
35. Gash D.M., Zhang Z., Avadia A., Cass W.A., Simmerman L., Russell D.S., Martin D., Lapchak P., Collins F., Hoffer B.J., Gerhardt G.A. Functional recovery in parkinsonian monkeys treated with GDNF. Nature 1996, 380:252-255.
36. Gibb W., Lees A. Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson's disease. J Neurol Neurosurg Psychiatry 1991, 54:388-396.
37. Gill S.S., Patel N.K., Hotton G.R., O'Sullivan K., McCarter R., Bunnage M., Brooks D.J., Svendsen C.N., Heywood P. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 2003, 9:589-595.
38. Gomide V., Bibancos T., Chadi G. Dopamine cell morphology and glial cell hypertrophy and process branching in the nigrostriatal system after striatal 6-OHDA analyzed by specific stereological tools. Int J Neurosci 2005, 115:582.
39. Gomide V., Silveira G., Chadi G. Transient and widespread astroglial activation in the brain after a striatal 6-OHDA-induced partial lesion of the nigrostriatal system. Int J Neurosci 2005, 115:99-117.
40. Gordon M.N., Schreier W.A., Ou X., Holcomb L.A., Morgan D.G. Exaggerated astrocyte reactivity after nigrostriatal deafferentiation in the aged rat. J Comp Neurol 1997, 388:106-119.
41. Gwinn R.P., Kondratyev A., Gale K. Time-dependent increase in basic fibroblast growth factor protein in limbic regions following electroshock seizures. Neuroscience 2002, 114:403-409.
42. Hagg T., Varon S. Ciliary neurotrophic factor prevents degeneration of adult rat substantia nigra dopaminergic neurons in vivo. Proc Natl Acad Sci USA 1993, 90:3619.
43. Henning J., Strauss U., Wree A., Gimsa J., Rolfs A., Benecke R., Gimsa U. Differential astroglial activation in 6-hydroxydopamine models of Parkinson's disease. Neurosci Res 2008, 62:246-253.
44. Ho A., Gore A.C., Weickert C.S., Blum M. Glutamate regulation of GDNF gene expression in the striatum and primary striatal astrocytes. Neuroreport 1995, 6:1454-1458.
45. Humpel C., Hoffer B., Strömberg I., Bektesh S., Collins F., Olson L. Neurons of the hippocampal formation express glial cell line-derived neurotrophic factor messenger RNA in response to kainate-induced excitation. Neuroscience 1994, 59:791-795.
46. Hurelbrink C.B., Barker R.A. The potential of GDNF as a treatment for Parkinson's disease. Exp Neurol 2004, 185:1-6.
47. Hyman C., Hofer M., Barde Y.-A., Juhasz M., Yancopoulos G.D., Squinto S.P., Lindsay R.M. BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature 1991, 350:230-232.
48. Ibáñes C.F. Beyond the cell surface: new mechanisms of receptor function. Biochem Biophys Res Commun 2010, 396:24-27.
49. Isaacs K.R., De Erausquin G., Strauss K.I., Jacobowitz D.M. Differential effects of excitatory amino acids on mesencephalic neurons expressing either calretinin or tyrosine hydroxylase in primary cultures. Mol Brain Res 1996, 36:114-126.
50. Kawamoto T., Nakamura S., Matsuo A., Akiguchi I., Shibasaki H. Immunohistochemical localization of glial cell line-derived neurotrophic factor in the human central nervous system. Neuroscience 2000, 100:701-712.
51. Kearns C.M., Cass W.A., Smoot K., Kryscio R., Gash D.M. GDNF protection against 6-OHDA: time dependence and requirement for protein synthesis. J Neurosci 1997, 17:7111-7118.
52. Kim J., Gale K., Kondratyev A. Effects of repeated minimal electroshock seizures on NGF, BDNF and FGF-2 protein in the rat brain during postnatal development. Int J Dev Neurosci 2010, 28:227-232.
53. Kirik D., Rosenblad C., Björklund A. Preservation of a functional nigrostriatal dopamine pathway by GDNF in the intrastriatal 6-OHDA lesion model depends on the site of administration of the trophic factor. Eur J Neurosci 2000, 12:3871-3882.
54. Kondratyev A., Sahibzada N., Gale K. Electroconvulsive shock exposure prevents neuronal apoptosis after kainic acid-evoked status epilepticus. Mol Brain Res 2001, 91:1-13.
55. Kondratyev A., Ved R., Gale K. The effects of repeated minimal electroconvulsive shock exposure on levels of mRNA encoding fibroblast growth factor-2 and nerve growth factor in limbic regions. Neuroscience 2002, 114:411-416.
56. Kordower J.H., Emborg M.E., Bloch J., Ma S.Y., Chu Y., Leventhal L., McBride J., Chen E.Y., Palfi S., Roitberg B.Z., Brown W.D., Holden J.E., Pyzalski R., Taylor M.D., Carvey P., Ling Z., Trono D., Hantraye P., Déglon N., Aebischer P. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of parkinson's disease. Science 2000, 290:767-773.
57. Korsching S. The neurotrophic factor concept: a reexamination. J Neurosci 1993, 13:2739-2748.
58. Kozlowski D.A., Connor B., Tillerson J.L., Schallert T., Bohn M.C. Delivery of a GDNF gene into the substantia nigra after a progressive 6-OHDA lesion maintains functional nigrostriatal connections. Exp Neurol 2000, 166:1-15.
59. Krieglstein K. Factors promoting survival of mesencephalic dopaminergic neurons. Cell Tissue Res 2004, 318:73-80.
60. Liberto C.M., Albrecht P.J., Herx L.M., Yong V.W., Levison S.W. Pro-regenerative properties of cytokine-activated astrocytes. J Neurochem 2004, 89:1092-1100.
61. Lie D.C., Dziewczapolski G., Willhoite A.R., Kaspar B.K., Shults C.W., Gage F.H. The adult substantia nigra contains progenitor cells with neurogenic potential. J Neurosci 2002, 22:6639-6649.
62. Lin L.-F.H., Doherty D.H., Lile J.D., Bektesh S., Collins F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 1993, 260:1130-1132.
63. Lipsky R.H., Marini A.M. Brain-derived neurotrophic factor in neuronal survival and behavior-related plasticity. Ann N Y Acad Sci 2007, 1122:143.
64. Love S., Plaha P., Patel N.K., Hotton G.R., Brooks D.J., Gill S.S. Glial cell line-derived neurotrophic factor induces neuronal sprouting in human brain. Nat Med 2005, 11:703-704.
65. Lu L., Wang X., Wu P., Xu C., Zhao M., Morales M., Harvey B.K., Hoffer B.J., Shaham Y. Role of ventral tegmental area glial cell line-derived neurotrophic factor in incubation of cocaine craving. Biol Psychiatry 2009, 66:137-145.
66. Mandel R.J., Spratt S.K., Snyder R.O., Leff S.E. Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats. Proc Natl Acad Sci USA 1997, 94:14083-14088.
67. Marco S., Canudas A.M., Canals J.M., Gavaldá N., Pérez-Navarro E., Alberch J. Excitatory amino acids differentially regulate the expression of GDNF, neurturin, and their receptors in the adult rat striatum. Exp Neurol 2002, 174:243-252.
68. Marini A.M., Rabin S.J., Lipsky R.H., Mocchetti I. Activity-dependent release of brain-derived neurotrophic factor underlies the neuroprotective effect of N-methyl-d-aspartate. J Biol Chem 1998, 273:29394-29399.
69. Mascó D.H., Sahibzada N., Switzer R., Gale K. Electroshock seizures protect against apoptotic hippocampal cell death induced by adrenalectomy. Neuroscience 1999, 91:1315-1319.
70. McGeer P.L., McGeer E.G. Glial reactions in Parkinson's disease. Mov Disord 2008, 23:474-483.
71. Miyazaki H., Nagashima K., Okuma Y., Nomura Y. Expression of glial cell line-derived neurotrophic factor induced by transient forebrain ischemia in rats. Brain Res 2001, 922:165-172.
72. Mughal M.R., Baharani A., Chigurupati S., Son T.G., Chen E., Yang P., Okun E., Arumugam T., Chan S.L., Mattson M.P. Electroconvulsive shock ameliorates disease processes and extends survival in huntingtin mutant mice. Hum Mol Genet 2011, 20:659-669.
73. Murray T., Messenger M., Ward M., Woodhouse S., Osborne D., Duty S., O'Neill M. Evaluation of the mGluR2/3 agonist LY379268 in rodent models of Parkinson's disease. Pharmacol Biochem Behav 2002, 73:455-466.
74. Guide for the care and use of laboratory animals 1996, National Academy Press, National Academy Press, Washington, D.C., USA.
75. Newton S.S., Collier E.F., Hunsberger J., Adams D., Terwilliger R., Selvanayagam E., Duman R.S. Gene profile of electroconvulsive seizures: induction of neurotrophic and angiogenic factors. J Neurosci 2003, 23:10841-10851.
76. Nibuya M., Morinobu S., Duman R.S. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci 1995, 15:7539-7547.
77. Nithianantharajah J., Hannan A.J. Enriched environments, experience-dependent plasticity and disorders of the nervous system. Nat Rev Neurosci 2006, 7:697-709.
78. Oo T.F., Kholodilov N.G., Burke R.E. Regulation of natural cell death in dopaminergic neurons of the substantia nigra by striatal glial cell line-derived neurotrophic factor in vivo. J Neurosci 2003, 23:5141-5148.
79. Oo T.F., Ries V., Cho J., Kholodilov N., Burke R.E. Anatomical basis of glial cell line-derived neurotrophic factor expression in the striatum and related basal ganglia during postnatal development of the rat. J Comp Neurol 2005, 484:57-67.
80. Paul G., Meissner W., Rein S., Harnack D., Winter C., Hosmann K., Morgenstern R., Kupsch A. Ablation of the subthalamic nucleus protects dopaminergic phenotype but not cell survival in a rat model of Parkinson's disease. Exp Neurol 2004, 185:272-280.
81. Paxinos G., Watson C. The rat brain in stereotaxic coordinates 2007, Elsevier, London, UK.
82. Peterziel H., Unsicker K., Krieglstein K. TGFβ induces GDNF responsiveness in neurons by recruitment of GFRα1 to the plasma membrane. J Cell Biol 2002, 159:157-167.
83. Popeo D., Kellner C.H. ECT for Parkinson's disease. Med Hypotheses 2009, 73:468-469.
84. Rangasamy S.B., Soderstrom K., Bakay R.A.E., Kordower J.H. Neurotrophic factor therapy for Parkinson's disease. Prog Brain Res 2010, 184:237-264.
85. Rasmussen K., Abrams R. Treatment of Pakinson's disease with electroconvulsive therapy. Psychiatr Clin North Am 1991, 14:925-933.
86. Saarma M., Sariola H. Other neurotrophic factor: glial cell line-derived neurotrophic factor (GDNF). Microsc Res Tech 1999, 45:292-302.
87. Sarabi A., Hoffer B.J., Olson L., Morales M. GFRα-1 mRNA in dopaminergic and nondopaminergic neurons in the substantia nigra and ventral tegmental area. J Comp Neurol 2001, 441:106-117.
88. Sariola H., Saarma M. Novel functions and signalling pathways for GDNF. J Cell Sci 2003, 116:3855-3862.
89. Satake K., Matsuyama Y., Kamiya M., Kawakami H., Iwata H., Adachi K., Kiuchi K. Up-regulation of glial cell line-derived neurotrophic factor (GDNF) following traumatic spinal cord injury. Neuroreport 2000, 11:3877-3881.
90. Sauer H., Oertel W.H. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat. Neuroscience 1994, 59:401-415.
91. Schallert T., Leasure J.L., Kolb B. Experience-associated structural events, subependymal cellular proliferative activity, and functional recovery after injury to the central nervous system. J Cereb Blood Flow Metab 2000, 20:1513-1528.
92. Schmidt-Kastner R., Tomac A., Hoffer B., Bektesh S., Rosenzweig B., Olson L. Glial cell-line derived neurotrophic factor (GDNF) mRNA upregulation in striatum and cortical areas after pilocarpine-induced status epilepticus in rats. Brain Res Mol Brain Res 1994, 26:325-330.
93. Shulman R.B. Maintenance ECT in the treatment of PD. Therapy improves psychotic symptoms, physical function. Geriatric 2003, 58:43-45.
94. Shults C.W., Ray J.R., Tsuboi K., Gage F.H. Fibroblast growth factor-2-producing fibroblasts protect the nigrostriatal dopaminergic system from 6-hydroxydopamine. Brain Res 2000, 883:192-204.
95. Smith A.D., Antion M., Zigmond M.J., Austin M.C. Effect of 6-hydroxydopamine on striatal GDNF and nigral GFRα1 and RET mRNAs in the adult rat. Mol Brain Res 2003, 117:129-138.
96. Spina M.B., Squinto S.P., Miller J., Lindsay R.M., Hyman C. Brain-derived neurotrophic factor protects dopamine neurons against 6-hydroxydopamine and N-methyl-4-phenylpyridinium ion toxicity: involvement of the gluthathione system. J Neurochem 1992, 59:99-106.
97. Sun M., Kong L., Wang X., Lu X.G., Gao Q., Geller A.I. Comparison of the capability of GDNF, BDNF, or both, to protect nigrostriatal neurons in a rat model of Parkinson's disease. Brain Res 2005, 1052:119-129.
98. Teissmann P., Tieu K., Cohen O., Choi D.-K., Wu D.C., Marks D., Vila M., Jackson-Lewis V., Przedborski S. Pathogenic role of glial cells in Parkinson's disease. Mov Disord 2003, 18:121-129.
99. Tomac A., Lindqvist E., Lin L.-F.H., Ogren S.O., Young D., Hoffer B.J., Olson L. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 1995, 373:335-339.
100. Tomac A., Widenfalk J., Lin L.-F.H., Kohno T., Ebendal T., Hoffer B.J., Olson L. Retrograde axonal transport of glial cell line-derived neurotrophic factor in the adult nigrostriatal system suggest a trophic role in the adult. Proc Natl Acad Sci USA 1995, 92:8274-8278.
101. Trupp M., Arenas E., Fainzilber M., Nilsson A.-S., Sieber B.-A., Grigoriou M., Kilkenny C., Salazar-Grueso E., Pachnis V., Arumäe U., Sariola H., Saarma M., Ibáñes C.F. Functional receptor for GDNF encoded by the c-ret proto-oncogene. Nature 1996, 381:785-788.
102. Ungerstedt U. 6-hydroxydopamine induced degeneration of central monoamine neurons. Eur J Pharmacol 1968, 5:107-110.
103. Unsain N, Montroull LE, Mascó DH (in press) Brain-derived neurotrophic factor facilitates TrkB down-regulation and neuronal injury after status epilepticus in the rat hippocampus. J Neurochem.
104. Vernon A.C., Palmer S., Datla K.P., Zbarsky V., Croucher M.J., Dexter D.T. Neuroportective effects of metabotropic glutamate receptor ligands in a 6-hydroxydopamine rodent model of Parkinson's disease. Eur J Neurosci 2005, 22:1799-1806.
105. Wei G., Wu G., Cao X. Dynamic expression of glial cell line-derived neurotrophic factor after cerebral ischemia. Neuroreport 2000, 11:1177-1183.
106. Yamagata K., Tagami M., Ikeda K., Tsumagari S., Yamori Y., Nara Y. Differential regulation of glial cell line-derived neurotrophic factor (GDNF) mRNA expression during hypoxia and reoxygenation in astrocytes isolated from stroke-prone spontaneously hypertensive rats. Glia 2002, 37:1-7.
107. Yurek D.M., Fletcher-Turner A. Differential expression of GDNF, BDNF, and NT-3 in the aging nigrostriatal system following neurotoxic lesion. Brain Res 2001, 891:228-235.
108. Zhou J., Yu Y., Tang Z., Shen Y., Xu L. Differential expression of mRNAs of GDNF family in the striatum following 6-OHDA induced lesion. Neuroreport 2000, 11:3289-3293.